secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0001493152-24-052600
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable
--------------------------------------------------------------------------------

- No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
- Low infectivity of H3N2 challenge strain made virology data uninterpretable; enrollment to be extended.
- Company plans to submit protocol amendment to UK MHRA to extend enrollment and ensure adequate infection rates.
- CC-42344 showed favorable safety/tolerability, but low infection rate hindered antiviral data analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/0001493152-24-052600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224052600/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-052600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer